Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

By K. Fizazi, H. Scher, A. Molina, C. Logothetis, K. Chi, Robert J. Jones, J. Staffurth, S. North, N. Vogelzang, F. Saad and 8 more. The Lancet Oncology, 2012

1,346 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/0517d69ab054cb2c73cc6548c278dc5fd08cf24b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. M. Hallek
2. Michel Bolla
3. N. Mottet
4. J. Bellmunt
5. Steven Joniau
6. Thomas Wiegel

Citations in the corpus

• Prostate Cancer (2018, methodology): “Prior studies have evaluated the ability of clinicians to predict life expectancy in patients with prostate cancer [33].”
• Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017, background): “5 3 ULN 72 (18) 26 (13) Not reported 1 (, 1) 0 Gleason score # 7 189 (47) 103 (51) $ 8 192 (48) 91 (45) Not reported 19 (5) 8 (4) PSA Patients with available PSA data 393 197”
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, background): “8 mo [125] and confirmed with further follow-up [126].”
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, background): “8 mo [92], and the final results have been reported more recently [93].”